Ranvir's Portfolio

Cello World -

Q1 FY 27 results and concall highlights -

Revenues - 527 vs 529 cr, flat YoY

Gross margins @ 52.4 vs 54 pc

EBITDA - 117 vs 126 cr, down 7 pc ( margins @ 22.2 vs 23.9 pc )

PAT - 73 vs 81 cr, down 10 pc

Exports as a percentage of revenues stood @ 7.3 pc

Notes from previous concalls -

By H2 FY 27 - company should start to see meaningful improvements in business momentum { due ramp up in glassware ( was running at 60 pc utilisation levels in Q3 )+ resolution of steelware bottlenecks + additional sales from Cello brand’s writing instruments }

Around 75 of products that the company sells are made in-house

Company believes, glassware is a long term bet for the company. This category should become large over next 4-5 yrs. There r pressures from imports but their quality is sub-optimal. Once the capacity ramps up beyond 75 pc - profitability improves dramatically

The Cello brand has a much better brand equity in the writing instruments mkt vs the UnoMax brand. This also gives the company to grow aggressively in the adjoining stationery mkt. Should be a big opportunity going forward

Revenue growth in H1 and H2 FY 27 should be in single digits and mid teens respectively. Relatively muted H1 FY 27 is due to the fact that full steelware capacities will only come online by H2 ( they ll keep coming on stream in phases ). Steelware’s initial capacities should be able to clock 300 cr kind of annual sales with an option for brownfield addition of manufacturing lines

Have commissioned 6 new steel bottles manufacturing lines over last 2 months ( end of Q4 and in Q1 ). Aim to commission 2 more lines in Q1

Lost 25 pc sales in the Hydra Steelware segment in FY 26 - due supply constraints

Operating @ 85 pc capacity utilisation in Opalware

Loss in steelware sales in FY 26 was around 75 cr ( ballpark estimate )

As the utilisation of their glassware plant improves, the profitability should get a bump. Glassware plant has a peak revenue potential of 300 cr with 25 pc kind of EBITDA margin potential

Trying to reduce their dependence on the Rs 10 / pen segment. Pushing the Rs 12/15/20 price points more aggressively. Also pushing markers, sketch pens, crayons etc to improve their profitability. Cello brand ( now acquired ) has great brand equity but was being run in a suboptimal fashion. Q1 and Q4 are the best Qtrs for the stationery business

Notes from Q1 concall -

Were able to hold onto gross margins ( by and large ) due price hikes taken by them in Q1

Writing instruments grew 52 pc YoY

Consumerware business reported a weak qtr led by overall demand weakness + absence of supply of many steelware SKUs because of which they had to let go of sales

Have commenced in-house manufacturing of steel bottles. 8 manufacturing lines are currently operational

Capacity utilisation in glassware hovered @ around 60 pc ( roughly @ EBITDA breakeven levels ). Scale up here has been weaker than expected ( primarily due Chinese dumping ). Once the capacity utilisations go to 75 pc or so, descent profitability outcomes should start to become visible

Glassware sales from this new facility improved 35 pc YoY but the capacity utilisation did not improve much as the company used up its old inventories

Glassware facility clocked 150 odd cr sales in FY 26. This yr sales should be meaningfully better than LY

Despite commencing production @ their new stemware plants, could not produce all types of items. Hence - continued to face stock out situations even in Q1 for various SKUs

Before BIS implementation ( when they were importing steelware ) they used to sell aprox 150 SKUs. Today they r down to 20 SKUs ( made in house ). Hope to exit the year with 50 + SKUs

Rough estimates - of sales lost in steelware division for full FY 26 @ 80-100 cr ( bulk of it in H2 as the imported inventories were available to service demand in H1 )

Price hikes taken by the company varied from 7 pc to 20 pc - product to product. Such steep price hikes led to volume de-growth in Q1

Moulded furniture is a slow growth / flattish category. Here the company aims to maintain revenues + profitability over medium territory

Sales loss in steelware category has been substantial in Q1 ( vs Q1 LY ) - which has also led to de-growth in overall consumer ware category for the company

No major capex lined up for FY 27 except for addition of a couple of more lines in steelware ( to be commissioned next FY ) + maintenance capex

Channel inventory has corrected in Q1 ( should help them in push more sales in Q2 )

Ramp up in steelware + glassware are two key things they need to ramp up in FY 27 and H1 FY 28. Both these should also help their profitability in a meaningful manner

Will be in a position to give a guidance for FY 27 at the end of Q2

Ex-Steelware, company’s consumerware business grew by 4-5 pc in Q1

Current GMs in steelware and glassware are on the lower side - as these facilities are in the ramp up stage. This is also a reason for YoY compression in GMs despite the price hikes taken by the company in other categories

Cash on books to be utilised to inorganic opportunities. They are always on the look out for the same. Nothing on the horizon at the moment

Disc: holding, biased, not SEBI registered, posted only for educational purposes

Disc :

Likes of Borosil Ltd, Cello World, CG Consumer Electricals, Surya Roshni, Insecticides India, Dhanuka Agritech continue to be laggards in my PF. Hoping ( not without reasons ) for a turnaround in their business performance going forward

Dhanuka and Insecticdes India’s stocks were beaten up in last FY due excessive rains. Got beaten up again due deficient rains in Q1. Don’t think there is anything to lose from here

Consumer discretionary spending dependent players like - Cello, Borosil, CG Consumer had a rough patch in last FY due overall weakness in consumer demand. Then got bashed up again due steep RM inflation due breakout of Iran war in Q1 this yr

List of good performers include - Yatharth Hospitals, Windlas Bio, Man Industries, Electronics Mart India, IIFL finance, Entero Healthcare, karur Vysya Bank ( where I also continue to hold )

10 Likes

Entero Healthcare is a good find. It is following the Patterson Companies model (which grew through multiple acquisitions in the US and UK) as distribution consolidated. This is a decadal opportunity if played right. Most likely will be taken private or get acquired by a major hospital chain (as Apollo is a major competitor in distribution). Good long term compounding opportunity

This space will be a hot bed of acquisition led growth as unorganized >> organised consolidation plays out..

4 Likes

Mahindra and Mahindra -

Company’s stakes in various group companies -

Mahindra Electric Automobile Ltd ( MEAL ) - 4W BEVs - 92 pc

Mahindra and Mahindra Fin services - 52 pc

Mahindra Lifescpace developers - 52 pc

Mahindra Logistics - 59 pc

Mahindra Holidays - 67 pc

SML Mahindra ( sell CVs > 3.5 T ) - 59 pc

Mahindra last mile mobility ( sell 3Ws and small BEV CVs ) - 78 pc

Swaraj Engines ( diesel engines ) - 52 pc

Classic legends ( Yezdi, Jawa, BSA ) - 58 pc

Mahindra EPC irrigation - 54 pc

Mahindra first choice wheels - 56 pc

Mahindra Aerospace and Defence - 100 pc

Tech Mahindra - 28 pc

Mahindra Manulife ( AMC + Life insurance ) - 51 pc

Q1 FY 27 results and concall highlights -

Revenues - 58.2 k vs 45.2 k cr, up 28 pc

EBITDA - 10.8 k vs 8.4 k cr, up 28 pc ( margins @ 19 vs 18 pc )

PAT - 5.4 k vs 4.08 k, up 35 pc ( bumped up by company’s stake sale in CIE Auto. Ex - stake sales, PAT would ve grown by 22 pc )

PAT contribution towards consol numbers from various businesses -

Auto - 2.12 k cr, up 21 pc ( includes PAT numbers of SML Mahindra and Mahindra Trucks and buses ltd )

Farm - 1.52 k cr, up 15 pc

M&M Fin Services - 486 cr, up 78 pc

Tech Mahindra - 411 cr, up 28 pc

Real Estate - 41 cr, up 2X

Logistics - 14 cr ( vs negative 7 cr in Q1 LY )

Investments - 772 cr, up 115 pc ( due gains realised on sale of M&M stakes in CIE automotives )

Imp commentary -

Board has approved merger of MTBD into SML in early Q2

SUV volumes grew 15 pc

Domestic farm equipment values grew by 18 pc, Export volumes of farm equipment grew by 15 pc. Company continues its mkt leadership in farm equipment segment with mkt share @ 45 pc

SML+MTBD - combined mkt share now @ 7.8 pc. Combined volumes grew by 11 pc

Notes from Q1 concall -

Reported strong results despite severe RM price inflation ( @ around 400-500 bps for key RMs )

M&M Finance’s asset quality and disbursement trends continue to remain strong. Gross Stage 3 assets have been below 4 pc of AUM for past 8 Qtrs in a row. Closed Q1 FY 27 @ 3.45 pc ( talking of GS 3 )

Labour shortage in farm / rural areas are structural drivers for growth in tractors and other farm equipment. Rabi cash flows have been healthy. This is keeping rural cashflows @ healthy levels. Rainfall shortages in June are now behind ( as the catch up in July/Aug has been encouraging ). Kharif sowing has picked up meaningfully over last 1 month

Domestic Farm ( core tractor ) business clocked 19 pc EBITDA margins with sales @ 9964 cr. EBITDA margins in international farm business were negative with sales @ 1735 cr ( also due impairment charged to P&L ). Other farm business like Farm machinery + Powerol + Swaraj Engines clocked 10.7 pc kind of EBITDA margins with sales @ 10.7 pc. Consol company level EBITDA margins in the overall farm business were @ 14.2 pc

Auto PV volumes sold in Q1 @ 1.75 lakh, up 15 pc YoY

LCV< 3.5 T volumes sold @ 74k, up 20 pc YoY

Consol EBIT margins of Auto business ( SUVs + LCVs<3.5T, EVs + Trucks and Buses and Last mobile connectivity solutions ) @ 7.7 vs 7.9 pc YoY

Auto Segmental Revenues and EBIT -

SUVs +LCVs < 3.5Ts - 25.16k cr, EBIT @ 8.9 vs 10.8 pc

EV SUVs - 5.4k cr, EBIT @ 5.3 vs (-) 3.3 pc

Trucks and Buses + Last mile connectivity - 4.19k cr, EBIT @ 2.3 vs (-) 2.9 pc

EVs ( 3W + 4W ) -last mile connectivity volumes - 35.5k vs 19.2k YoY

ICE ( 3W + 4W ) last mile connectivity volumes - 6.7k vs 5.8k YoY

SML volumes - 5.4k vs 4.3k YoY

MTB volumes - 3.9k vs 3.4k YoY

Tractor volumes - 1.58 lakh, up 18 pc YoY ( domestic mkt share @ 45 pc )

Non Auto business of M&M finance ( mortgages, PLs, SME loans ) grew by 79 pc YoY in Q1. Auto loans ( PVs + Tractors + CVs ) grew by 21 pc

12 pc of all PVs sold by the company were electric. Company’s EV business is EBITDA positive even without PLI benefits

As company’s volumes improve, their EV profitability should only improve. Plus - as the consumers start to realise that they r gonna save significant amount of money by using an EV vs a petrol car and this mentality gains momentum, company can always start charging premium for Electric Vehicles

Mahindra lifespace ( RE subsidiary ) - intend to keep focusing on Mumbai, Bengaluru and Pune. Shall keep trying to improve their depth in these 3 cities instead of spreading themselves thinly over many cities

Took 1.5 pc price hike in Q1 followed by another 2.7 pc price hike in early Q2. This should support margins ( to some extent ) vs Q1

Despite the recent price hikes taken by the company - prices r still below vs LY ( before GST rate cuts )

M&M finance AUM now @ aprox 1.5 lakh cr. 83 pc of the AUM comes from Auto lending ( PVs + CVs + Tractors + Used Vehicles ). Aim to grow the non auto business to 30 pc of AUM by 2030

Company’s Aerostructure order book stands @ $ 1.2 billion and growing fast. Revenues right now aren’t comparable to their large order book because it takes time for order executions. Aspire to grow their aero structures business by > 30X over next 10 yrs ( organic + inorganic combined )

Commodity price pressures are more severe in Farm vs Auto business. Two reasons - there is no way to hedge the steel and rubber - both r used more extensively in farm business. In auto business - they do hedge their Aluminium requirements. Secondly - Aluminium prices have started correcting but not Steel and Rubber

Disc: holding, biased, not SEBI registered, posted only for educational purposes

2 Likes

Very good update effort @ranvir :folded_hands:. Request if admins could post this under Mahindra & Mahindra Stock Opportunities page as well.

Insecticides India -

Q1 FY27 results and concall highlights -

Revenues - 612 vs 691 cr, down 12 pc

GMs @ 31.6 vs 29 pc

EBITDA - 68 vs 85 cr, down 20 pc ( margins @ 11 vs 12 pc )

PAT - 44 vs 58 pc

Notes from previous concalls -

No of focus Maharatna brands @ 16 ( mostly have a pan India presence )

No of Maharatna brands @ 43 ( relatively smaller, regional brands )

These Maharatna + Focus Maharatna products have gross margins > 35 pc vs 15 - 20 pc for plain vanilla generics

Manufacturing footprint -

3 - Active ingredients plants ( @ Chopanki, Sotanala and Dahej )

6 - Formulation plants ( @ Chopanki, Dahej - 1, Dahej -2, Udhampur, Samba, Sotanala )

1 - Biologics plant ( Shamli )

4 - R&D centers

Sotanala AI plant expected to go live in Q4 FY 27. Sotanala Formulations plant should go live in Q3 FY 27

Most of the AIs ( > 70 pc ) that go into Maharatna + Focus Maharatna products are made in house or sourced through their MNC collaboration partners

Backward Integration in AI manufacturing is a continuous process that the company engages in { they keep going back in terms of performing N-1, N-2, N-3, N-4 ( and so on ) steps - in house as the molecule’s traction keeps improving }

Expanding their technicals manufacturing capacities and deepening the backward integration of technicals is a conscious decision that the company has made

Company’s list of In-Licensed products -

From Nissan Chemical Corp - 7 ( Pulsar, Hakama, Kunoichi, Hachiman, Shinwa, Izuki, Altair )

From Corteva - 2 ( Sparkle, Granuvia )

From Nihon Nohyaku - 3 ( Suzuka, Hakko, Aikido )

From OAT Agrio - 2 ( Root Bead, Tadaaki )

From American Vanguard Corp - 2 ( Thimet and Nuvan - branded generics )

From Momentive - 1 ( Spread Max - its a super spreader added to the spray to improve its coverage )

Expected to launch 8th product - in licensed from Nissan in the upcoming Kharif season

Shall be launching Spinoace ( bio insecticide ) and GreenMix ( herbicide ) in FY 27 - in licensed from Corteva

After the Sotanala projects are commissioned - their capex requirements should taper off for next 2-3 yrs

Revenues from Patented products + in licensed products for FY 26 @ 546 cr

Also expected to launch another patented product in FY 27 - in licensed from OAT Agrio

Maharatna + Focus Maharatna products contributed to 63 pc of company’s B2C sales in FY 26 ( that would be aprox 50 pc of company’s total revenues ). That’s roughly 1050 cr in sales. Aim to take this contribution up to 70 pc in next 2-3 yrs

Notes from Q1 concall -

Launched Spinoace ( bio - insecticide ) in Q1

Premium products sales as a mix of B2C sales stood @ 64 pc. B2C sales represented 65 pc of company sales in Q1 ( vs 75 pc in Q1 LY ). Rest coming from B2B and Export sales

Total investment outlay for Sotanala Formulations + AI plant should be 50 + 150 = 200 cr. Have already spent 70 cr. Post this capex, company’s capex intensity should come down meaningfully ( to levels of 30-40 cr / yr - basically maintenance capex

Seeing a descent recovery in demand outlook post the weakness seen in Q1. Still guiding for full yr revenues > LY ( despite a very weak Q1 )

Sales returns in current FY ( post Q2 ) should be far lower vs LY as they r being far more cautious wrt placements in current Qtr

Volume de-growth in Q1 was @ 14 pc. Value growth was 2 pc

Expecting Granuvia and Spinoce to clock sales of 20 cr and 10 cr respectively in FY 27

Disc: holding, biased, posted only for educational purposes

1 Like

EMIL -

Q2 FY 27 results and concall highlights -

Pre Ind AS results -

Revenues - 1899 vs 1591 cr, up 19.4 pc

Gross margins - 15.4 vs 14.1 pc

EBITDA - 90 vs 45 cr, up 100 pc ( margins @ 4.8 vs 2.9 pc ). Reported EBITDA ( post Ind AS ) @ 130 vs 90 cr, up 60 pc

PAT - 53 vs 28 cr. Reported PAT ( post Ind AS ) @ 40 vs 16 cr, up 148 cr

Cluster wise Q2 revenues -

Hyderabad - 1065 cr, up 16 pc, SSSG@ 15.4 pc

Telangana - 264 cr, up 17 pc, SSSG@ 13.4 pc

AP - 301 cr, up 24 pc, SSSG@ 17.7 pc

NCR - 166 cr, up 46 pc, SSSG@ 32.4 pc

Total no of stores @ 229. Mature stores ( > 4 yrs old ) @ 102 stores

Mature:Non Mature store revenues @ 2975:1136 cr

Mature:Non Mature store H1 EBITDA @ 289:72 cr

Mature:Non Mature store H1 EBITDA margins @ 9.7:6.4 pc

North Cluster EBITDA margins @ 3.4 pc for H1

South Cluster EBITDA margins @ 9.3 pc for H1

No of bill cuts grew by 3.4 pc

Avg ticket size grew by 14.6 pc

Notes from Q2 concall -

Avg capex per store ( of size 10k sq ft ) - 2.5 ( interiors, fixtures ) + 2.5 ( inventory ) = 5 cr. They r comfortable with paying 3 pc of revenues as rentals, 1 pc of revenues as employee costs ( while opening a new store )

H1 revenue growth @ 29.7 pc

GM in H1 @ 16.4 pc, up 210 bps

Q2 reported EBITDA margins @ 6.9 vs 5.1 pc

H1 reported EBITDA margins @ 8.6 vs 5.7 pc

Have added a total of 6 stores in H1 FY 27

As the onset of festive season has been delayed this yr ( vs Q2 LY )

By second week of Nov, should be able to open 4-5 stores in WB ( and kick off their business in this state )

Should be able to open another 20 stores in H2

Aim to take the total no of stores in WB to > 15 stores in next 6-9 months

GMs in H1 were strong as the company saw continuous prices hike across product categories across H1 which gave them descent inventory gains. H1 GMs were @ 16.4 pc. Aim to clock 15 pc kind of GMs in H2

Seeing some pressure on the volumes in entry level mobiles and appliances. Seeing no such pressures @ the premium end ( across their product range )

Have hired a no of ppl for their Kolkata ops + have hiked wages after almost 2 yrs. Hence the overall employee costs r up by 18 pc

Guiding for 7.5 pc consol post Ind AS EBITDA margins for full yr FY 27

Demand scenario is holding up well in Oct ( ie on expected lines )

Maintaining a 20 pc plus revenue guidance for full FY ( have already clocked 29 pc revenue growth in Q1. I think, their guidance is on the conservative side )

Disc: holding, largest position > 10 pc of PF, biased, not SEBI registered, not a buy/sell recommendation

1 Like

Rainbow Children’s Medicare -

Q2 FY 27 results and concall highlights -

Revenues - 548 vs 444 cr, up 23 pc

EBITDA - 170 vs 148 cr, up 14 pc ( margins @ 31 vs 33.5 pc )

PAT - 84 vs 76 cr, up 10 pc

Total mature hospitals ( > 5 yrs ) @ 14, contributing to 73 pc of group revenues

Total emerging hospitals ( > 2 yrs ) @ 7, contributing to 22 pc of group revenues

New hospitals ( < 2 yrs ) @ 5, contributing to 4 pc of group revenues

Speciality Mix -

Women care @ 30 pc

Pediatrics @ 65 pc

IVF @ 5 pc

Current status of company’s hospitals -

Hyderabad + Telangana - 8 hospitals and 2 clinics in Hyderabad + 1 hospital in Warangal

Bengaluru - 6 hospitals + 2 IVF centers + 1 clinic

NCR - 1 hospital ( excludes Malvia Nagar hospital where the company provides medical services )

AP - 3 hospitals + 2 Hospitals ( went live in Q2 )

NE - 1 hospital

Chennai - 3 hospitals

Hospitals slated to open - In FY 27 -

Nellore - 70 beds - went live in Q2 FY 27

Guntur - 50 beds - went live in Q2 FY 27

Indore - 25 beds - should go live in Q3 FY 27

Total - 145 beds

In FY 28 -

Coimbatore - 130 beds

Gurugram ( sec 56 ) - 125 beds

Nellore - 30 beds

Mumbai ( Malad ) - 100 beds

Total - 385 beds

In FY 29 -

Seegehalli - 80 beds

Gurugram ( sec 44 ) - 325 beds

Indore - 75 beds

Pune - 150 beds

Total - 630 beds

Notes from previous concalls -

Nellore and Guntur hospitals ( 70 + 50 beds ) are new acquisitions made in Q1. This shall bump company’s operational beds in AP to 500 beds

Plan to add 2500 beds over next 5 yrs to hit 5000 beds by 2031-32. Should end up spending aprox 2000 cr to fund this capex. Already have a visibility of 1200 beds - under various stages of development ( as brought out above )

Operational beds @ the end of FY 27 should be > 2000 beds

Aim to have 5 hub hospitals @ the end of 5 yrs from now ( ie when they have 5000 beds ). These 5 hubs shall be located @ Bengaluru, Hyderabad, Chennai, Gurugram and 1 more city

Expect their ARPOBs to clock a 5 pc kind of CAGR for next 5 yrs

Should be able to double their revenues in next 4 yrs @ 20 pc CAGR

Notes from Q2 concall -

Have been alloted with 2 acres of land by AP govt - to build a new paediatric hospital in the new capital city @ Amravati

For H1, revenue/EBITDA/PAT growth stood @ 26 pc, 21 pc and 13 pc respectively

Cash on books @ 543 cr as on 30 Sep - should help them support their capex going forward

Capex spends in Q2 @ 89 cr

Q2 occupancy @ 49 vs 52 pc, down 5 pc

ARPOB @ 63.4k, up 10 pc

No of operational beds @ 1910, up 18 pc

Total deliveries @ 5719, up 20 pc

Marketing spends @ 2 pc of revenues

Recent price cap on Onco drugs doesn’t affect Rainbow Hospitals

Max occupancy that the company expects their mature hospitals to hit is around 60 pc

Most of their new hospitals turn EBITDA positive between 12-24 months ( depending on location to location )

Confident of maintaining similar / slightly better margins going forward - critical to monitor these as bottomline growth has been trailing the topline growth for last 2 Qtrs

For M&A opportunities, company pays @ max an EV/EBITDA multiple of 10-12. They r open to inorganic growth going forward

Margins in current FY have been adversely affected by incremental sales and marketing spends that the company has been indulging in ( have spent aprox 5-6 cr extra in H1 FY 27 vs H1 LY )

Looking @ full yr EBITDA margins ( post IndAS ) of 30-31 pc for full FY 27

Assumptions - Revenue in H1 has grown by 26 pc. Let’s assume a 17 pc revenue growth in H2 and a 31 pc post IndAS EBITDA margin for full FY 27. A back of the envelop calculation - full yr EITDA and PAT should grow by 19 pc and 12 pc respectively. PAT dragged down mostly by lower ETR in last FY @ 21 pc vs 25 pc ETR in FY 27

Disc: holding, core investment position, not SEBI registered, not a buy / sell recommendation

2 Likes

Entero Healthcare -

Q2 FY 27 results and concall highlights -

Revenues - 2087 cr, up 33 pc

Gross margins @ 11.5 vs 10.2 pc ( GMs in Q1 were @ 11.4 pc )

EBITDA - 112 cr, up 78 pc ( margins @ 5.3 vs 4 pc ). Margins in Q1 were @ 5 pc

PAT - 61 cr, up 66 pc

For H1 - Revenues, EBITDA and PAT are up by 35pc , 85 pc and 70 pc respectively

In FY 27, revenues from MedTech are expected to cross 1000 cr. Med Tech is a faster growth, higher margin segment

IPM growth in H1 was @ 14.5 pc

No of retailers being supplied by the company now @ 92.2k vs 85.3k on 30 Sep LY. No of hospitals being served @ 2900+ vs 2800+ LY. Total warehouses now @ 148 vs 113 LY

Organic growth in Q2 was @ 18 pc. Another 15 pc was contributed by acquisitions made LY ( and were not in the base numbers in Q2 LY )

Company is 3rd largest pharma distributor in India. Other 2 being - Keimed ( Apollo group ), Ascent ( Pharmeasy group ). These 3 combined hold aprox 10 pc mkt share in IPM

Notes from previous concalls -

Med Tech is a margin accretive space. Should aid their gross and EBITDA margins going forward. It’s also a high growth area. Have continuously been making acquisitions in this space. These Med Tech companies deal in products like - Imaging consumables, Medical consumables, Ortho + Cardio consumables, In Vitro diagnostics etc

Med Tech business has much better gross margins. However, the company also has to work towards demand generation and doctor awareness in the Med Tech business ( unlike in normal pharma distribution ). So that’s a cost that the company has to incur

Company has a ready pipeline of potential acquisition targets ( in the range of 100 cr per transaction or so ). Whenever the company again decides to press the inorganic button, the available opportunities are already ready

Non Controlling Interest @ 26 pc of PAT. Company has pre-agreed call options to acquire the residual stakes in the acquisitions they have made in the past @ valuations in line with the valuations at the time of acquisition

Even if the company goes slow on acquisitions from here on, they should be able to grow @ 20 pc CAGR in a sustainable manner. They believe, they have built the requisite scale and tech platform to keep attracting customers and to keep growing at the projected rates ( ie 20 pc or so )

It’s not that the inorganic opportunities are not available for the company. In fact, the no of distributors who are ready to sell are plenty. It’s just an internal assessment by the company that their platform and mkt position is now good enough to keep growing at a brisk pace without indulging in aggression on the inorganic side. They ll still keep their eyes and ears open to good opportunities coming their way

As company keeps growing @ 20 pc kind of levels ( over next 3-4 yrs ), their cost base won’t grow @ those levels. Naturally, the EBITDA margins should keep expanding

Notes from Q3 concall -

No acquisitions done in H1 FY 27

Had earlier stated a revenue growth tgt for FY 27 @ 23 pc. They are now confident of exceeding that with 5 pc + EBITDA margins

Onco drug price caps are not gonna affect Entero’s margins in any meaningful manner. These margins were basically being kept by the customers ( Hospitals ) and not distributors

Guiding for converting 50 pc of their EBITDA to OCF for FY 27

Minority interest is only gonna reduce progressively going forward ( over next 2-3 yrs ) as company buys out the minority stakes

Going forward - would deploy free cash to either buy out minority stakes / make fresh acquisitions

In H2 impact of calendarisation would be far lower vs H1. Hence, there would be some moderation in topline growth. However, that would be offset if they make fresh acquisitions in H2

Assumption - A 27 pc revenue growth for full FY 27 for Entero and EBITDA margin of 5.1 pc, full yr EBITDA and PAT should be around 425 cr and 230 cr respectively ( before minority interest )

Board has a mandate to not exceed 2 on Net Debt / EBITDA

Don’t intend to acquire anything less than 100 cr in deal value

Disc: core holding, biased, not a buy/sell recommendation, posted only for educational purposes